Novel Therapy Yields High Remission and Response Rates in Pediatric R/R B-ALL
Bicistronic CD19/CD22 CAR T-cell therapy had improved safety, durability, and high remission rates in pediatric patients with R/R B-ALL.
Bicistronic CD19/CD22 CAR T-cell therapy had improved safety, durability, and high remission rates in pediatric patients with R/R B-ALL.
Full of stamina and determination, Lynn Lippert supported others and did what she loved through 24 years of living with metastatic breast cancer. Lippert’s life…
Art remains a vital part of Fox Chase Cancer Center’s culture. From the symbolic sculpture, The Diamond, greeting visitors outside the main entrance to the…
An abstract is unavailable.
Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve…
Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.
Pancreatic cancer survival rates have more than doubled in the past decade. It’s not because of a single breakthrough, but better knowledge of the cancer,…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
By W. Kimryn Rathmell Director, National Cancer Institute Dr.
$50,000 over one year for researchers that seek to stimulate creative approaches to translate basic research into new treatment options for kidney cancer.
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…